India Faces GLP-1 Drug Boom: Access vs. Regulation

India's public health landscape is poised for a significant shift as the patent for semaglutide expires. This development paves the way for domestic manufacturers to introduce generic versions of GLP-1 receptor agonists, commonly known through brands like Ozempic and Wegovy. These medications are crucial for managing Type-2 diabetes, promoting weight loss, and reducing cardiovascular risk.

The introduction of approximately 50 new generic brands is anticipated to lower drug costs substantially, potentially by one-third to one-fifth of current prices. This increased affordability promises wider access for middle- and lower-income patients, addressing India's escalating diabetes and obesity epidemics.

However, this increased accessibility presents regulatory challenges. The potential for misuse, driven by the drugs' weight-loss reputation, is a concern. Ensuring that these potent medications are used appropriately, with clear eligibility criteria and robust monitoring, is paramount. India must balance affordability with stringent oversight to prevent inequities and ensure patient safety.

Existing regulations classify GLP-1 medicines as Schedule H drugs, requiring a prescription. To counter the risk of over-the-counter sales, tighter prescription protocols and enhanced pharmacovigilance systems are essential. Clear advertising guidelines are also needed to present these as serious therapies, not lifestyle shortcuts. Regulatory foresight can help India set a global standard for equitable healthcare access.